As we are ever more acutely aware of the threats of antibiotic-resistant superbugs such as MRSA and C. difficile it has become more widely accepted that new drugs are needed which act upon new microbial targets. However, the cost to pharma of developing a new antibiotic - which could be rendered useless before the investment in its discovery has been recouped - has meant that many companies have no new drugs in the pipeline and more worryingly, have no active research in the area.
This timely, focused meeting built upon the highly successful event in 2008 attended by over 170 delegates.
Themes
The conference was split into two half-day sessions on the following themes:
Clinical Problems
Solutions and New Antibiotics
Aims
The conference brought together scientists and clinicians from a range of sectors including the pharmaceutical industry, the NHS, academia, charities and funding councils. It was hoped that this meeting would be a focal point to discuss the critical issues that underpin the future of antibiotics; the clinical impact of hospital acquired infection; the development of new classes of antibacterials, the identification of novel targets and the solutions to the scientific and commercial obstacles to antibiotic research.
CPD Accreditation
The Royal College of Physicians approved the allocation of 5 credits to Antibiotics 2011 - Where Now? as a continuing Professional Development activity (approval code 58447).
Delegates may choose to receive a certificate confirming the CPD accreditation after the meeting.
Sponsorship & Exhibition
We would like to thank Forest Laboratories UK Ltd and BBSRC for their generous support of Antibiotics 2011 - Where Now?
Forest Laboratories UK Ltd also exhibited at this event.
Scientific Committee
Dominic Campopiano (Chair)
University of Edinburgh, UK
David Spring
University of Cambridge, UK
Jodi Lindsay
St George's University of London, UK
This timely, focused meeting built upon the highly successful event in 2008 attended by over 170 delegates.
Themes
The conference was split into two half-day sessions on the following themes:
Clinical Problems
Solutions and New Antibiotics
Aims
The conference brought together scientists and clinicians from a range of sectors including the pharmaceutical industry, the NHS, academia, charities and funding councils. It was hoped that this meeting would be a focal point to discuss the critical issues that underpin the future of antibiotics; the clinical impact of hospital acquired infection; the development of new classes of antibacterials, the identification of novel targets and the solutions to the scientific and commercial obstacles to antibiotic research.
CPD Accreditation
The Royal College of Physicians approved the allocation of 5 credits to Antibiotics 2011 - Where Now? as a continuing Professional Development activity (approval code 58447).
Delegates may choose to receive a certificate confirming the CPD accreditation after the meeting.
Sponsorship & Exhibition
We would like to thank Forest Laboratories UK Ltd and BBSRC for their generous support of Antibiotics 2011 - Where Now?
Forest Laboratories UK Ltd also exhibited at this event.
Scientific Committee
Dominic Campopiano (Chair)
University of Edinburgh, UK
David Spring
University of Cambridge, UK
Jodi Lindsay
St George's University of London, UK
